# Mereo Biopharma (MREO) — Overview

MREO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/mreo

## Price

Last close $0.31 on Oct 15, 2026. 52-week range $0.24 – $2.31.

## Company profile

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

## Financials

| Metric | Value |
| --- | --- |
| Revenue (trailing twelve months) | $0.00 |
| Revenue (quarter) | $0.00 |
| Revenue growth (year over year) | 0.00% |
| Gross profit (trailing twelve months) | $0.00 |
| Gross margin | 0.00% |
| Net income (trailing twelve months) | $0.00 |
| Net income (quarter) | −$7.0M |
| Net income growth (year over year) | 52.07% |
| Net margin | 0.00% |
| Return on equity | -67.85% |
| EPS (trailing twelve months) | −$0.20 |
| Book value per share | $0.18 |
| P/E (trailing twelve months) | — |
| Price to book | 1.7 |
| Debt to assets | 17.46% |
| Payout ratio | 0.00% |
| Dividend yield | 0.00% |

## Frequently Asked Questions

### How do I buy stock in Mereo Biopharma (MREO)?

MREO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).